Wechselwirkungen · Viread
Viread 33 mg/g granules · Abschnitt 4.5 · PDF-Seite 177–178
HOS-110883 · Präparat HOS-093385
177 Medicinal product by Effects on drug levels Recommendation concerning therapeutic areas Mean percent change in AUC, co-administration with 245 mg (dose in mg) Cmax, Cmin tenofovir disoproxil Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma concentrations (400 mg/100 mg q.d.) + AUC: ↔ of tenofovir resulting from Atazanavir/Ritonavir Cmax: ↔ co-administration of tenofovir (300 mg q.d./100 mg q.d.) + disoproxil, sofosbuvir/velpatasvir Emtricitabine/Tenofovir disoproxil GS-3310072: and atazanavir/ritonavir may (200 mg/245 mg q.d.) AUC: ↔ increase adverse reactions related Cmax: ↔ to tenofovir disoproxil, including Cmin: ↑ 42% renal disorders. The safety of tenofovir disoproxil when used Velpatasvir: with sofosbuvir/velpatasvir and a AUC: ↑ 142% pharmacokinetic enhancer (e.g. Cmax: ↑ 55% ritonavir or cobicistat) has not Cmin: ↑ 301% been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 8c5bfc7487f3120d6f6d4e1bd70dadd7df5fdcf39b1e407d38e2a8ce0c91ea11 · Zeichen 18608–20192 im Abschnitt